https://www.selleckchem.com/pr....oducts/ifenprodil-ta
6-3.9]), and nonusers (3.8 [3.7-4.0]). The aHR for DPN was 1.05 (0.98-1.11) in new users and 0.97 (0.91-1.04) in prevalent users compared with statin nonusers. New users had a slightly increased DPN risk during the first year (1.31 [1.12-1.53]), which vanished after 2 years of follow-up. Findings were similar in on-treatment and propensity score-matched analyses and with additional adjustment for pretreatment blood lipid levels. Statin therapy is unlikely to increase or mitigate DPN risk in patients with type 2 diabetes,
Like
Comment
Share
